These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16205246)

  • 21. The risk revolution: an examination of the regulatory environment.
    Morris LA
    J Am Pharm Assoc (Wash); 2001; 41(6 Suppl 1):S5-10. PubMed ID: 11764275
    [No Abstract]   [Full Text] [Related]  

  • 22. How the FDA manages drug safety with black box warnings, use restrictions, and drug removal, with attention to gastrointestinal medications.
    Ehrenpreis ED; Ciociola AA; Kulkarni PM;
    Am J Gastroenterol; 2012 Apr; 107(4):501-4. PubMed ID: 22475958
    [No Abstract]   [Full Text] [Related]  

  • 23. The importance of physicians identifying and reporting adverse drug events.
    Gatti JC
    Am Fam Physician; 2012 Feb; 85(4):318. PubMed ID: 22335311
    [No Abstract]   [Full Text] [Related]  

  • 24. Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data.
    Sarangdhar M; Tabar S; Schmidt C; Kushwaha A; Shah K; Dahlquist JE; Jegga AG; Aronow BJ
    Nat Biotechnol; 2016 Jul; 34(7):697-700. PubMed ID: 27404875
    [No Abstract]   [Full Text] [Related]  

  • 25. Drug Manufacturers' Delayed Disclosure of Serious and Unexpected Adverse Events to the US Food and Drug Administration.
    Ma P; Marinovic I; Karaca-Mandic P
    JAMA Intern Med; 2015 Sep; 175(9):1565-6. PubMed ID: 26214395
    [No Abstract]   [Full Text] [Related]  

  • 26. Setting the record straight...
    Singleton KA
    Medsurg Nurs; 2009; 18(5):262, 308. PubMed ID: 19927959
    [No Abstract]   [Full Text] [Related]  

  • 27. Predictability of serious adverse reaction alerts for monoclonal antibodies.
    Stanulovic V; Zelko R; Kerpel-Fronius S
    Int J Clin Pharmacol Ther; 2011 Mar; 49(3):185-90. PubMed ID: 21329620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 'Dear Healthcare Professional' letters may not be effective REMS communication tool.
    Thompson CA
    Am J Health Syst Pharm; 2014 Feb; 71(3):177-8. PubMed ID: 24429006
    [No Abstract]   [Full Text] [Related]  

  • 29. 'Extreme duplication' in the US FDA Adverse Events Reporting System database.
    Hauben M; Reich L; DeMicco J; Kim K
    Drug Saf; 2007; 30(6):551-4. PubMed ID: 17536881
    [No Abstract]   [Full Text] [Related]  

  • 30. Improving detection of adverse effects of marketed drugs.
    Klein DF; O'Brien CP
    JAMA; 2007 Jul; 298(3):333-4. PubMed ID: 17635895
    [No Abstract]   [Full Text] [Related]  

  • 31. How the FDA handles GI drug safety.
    Lewis JH
    Am J Gastroenterol; 2012 Aug; 107(8):1264; author reply 1264-5. PubMed ID: 22859005
    [No Abstract]   [Full Text] [Related]  

  • 32. Why were NIH adverse event reporting guidelines misunderstood?
    Finn R
    J Natl Cancer Inst; 2000 May; 92(10):784-6. PubMed ID: 10814665
    [No Abstract]   [Full Text] [Related]  

  • 33. The present status of adverse drug reaction reporting.
    Weston JK
    JAMA; 1968 Jan; 203(1):35-7. PubMed ID: 5694081
    [No Abstract]   [Full Text] [Related]  

  • 34. New FDA initiatives.
    Somberg JC
    J Clin Pharmacol; 1993 Jul; 33(7):587. PubMed ID: 8366185
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical recognition of adverse drug reactions: obstacles and opportunities for the nursing profession.
    Arnold GJ
    J Nurs Care Qual; 1998 Dec; 13(2):45-55; quiz 86-7. PubMed ID: 9842175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Report slams US FDA's drug safety reform efforts.
    Bristol N
    Lancet; 2007 Mar; 369(9567):1072. PubMed ID: 17405202
    [No Abstract]   [Full Text] [Related]  

  • 37. Anatomy of Risk Evaluation and Mitigation Strategies (REMS).
    Loeser KK; McKoy JM; Schumock GT
    Cancer Treat Res; 2019; 171():93-105. PubMed ID: 30552659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The benefits of data mining.
    Bone A; Houck K
    Elife; 2017 Aug; 6():. PubMed ID: 28813246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety concerns at the FDA.
    Lancet; 2005 Feb 26-Mar 4; 365(9461):727-8. PubMed ID: 15733696
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.